Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525143 | 0.94 | EGFR (0.69) | EGFRERBB2 | |
| SCHEMBL3522831 | 0.92 | EGFR (0.65) | EGFRERBB2 | |
| SCHEMBL3525133 | 0.92 | EGFR (0.65) | EGFRERBB2 | |
| SCHEMBL4735610 | 0.92 | EGFR (0.65) | EGFRERBB2 | |
| SCHEMBL4732086 | 0.92 | EGFR (0.62) | EGFRERBB2 | |
| SCHEMBL3519411 | 0.92 | EGFR (0.62) | EGFRERBB2 | |
| SCHEMBL1675982 | 0.90 | EGFR (0.61) | EGFRERBB2ERBB4 | |
| SCHEMBL3524444 | 0.90 | EGFR (0.63) | EGFRERBB2 | |
| SCHEMBL3525158 | 0.90 | EGFR (0.63) | EGFRERBB2 | |
| SCHEMBL3522078 | 0.90 | EGFR (0.61) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659279-B2 | 2-{(2S)-2-[({4-[3-Chloro-4-fluoroanilino]-7-methoxyquinazolin-5-yl}oxy)methyl]pyrrolidin-1-yl}-2-oxoethanol; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; breast, colorectal and head and neck cancer | ASTRAZENECA AB (SE) | 2010-02-09 | — | — | US | disclosed |
| EP-1622620-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
| EP-1622620-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096226-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885ERBB4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.